Register
Journal Updates
eMediNexus Coverage from: 
FDA approves Revcovi for adenosine deaminase severe combined immune deficiency
eMediNexus,  10 October 2018
remove_red_eye 578 Views
#Pathology and Lab Medicine #Pharmacist

0 Read Comments                

The US Food and Drug Administration (FDA) has approved elapegademase-lvlr (Revcovi, Leadiant Biosciences) for the treatment of adults and children with adenosine deaminase severe combined immune deficiency.
To continue reading this article
Sign in with Medtalks

Continue reading your article with a eMediNexus account.
Free Membership!